SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial
Kimberly A. Kraynyak, Elliott Blackwood, Joseph Agnes, Pablo Tebas, Mary Giffear, Dinah Amante, Emma L. Reuschel, Mansi Purwar, Aaron Christensen-Quick, Neiman Liu, Viviane M. Andrade, Malissa C. Diehl, Snehal Wani, Martyna Lupicka, Albert Sylvester, Matthew P. Morrow, Patrick Pezzoli, Trevor McMullan, Abhijeet J. Kulkarni, Faraz I. Zaidi, Drew Frase, Kevin Liaw, Trevor R.F. Smith, Stephanie J. Ramos, John Ervin, Mark Adams, Jessica Lee, Michael Dallas, Ami Shah Brown, Jacqueline E. Shea, J. Joseph Kim, David B. Weiner, Kate E. Broderick, Laurent M. Humeau, Jean D. Boyer, Mammen P. Mammen Jr.
medRxiv 2021.10.06.21264584; doi: https://doi.org/10.1101/2021.10.06.21264584